Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms

on behalf of the Mayo Clinic Histiocytosis Working Group

doi:10.1182/blood-2018-12-893917

Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms

on behalf of the Mayo Clinic Histiocytosis Working Group

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1607-1610
Number of pages	4
Journal	Blood
Volume	133
Issue number	14
DOIs	https://doi.org/10.1182/blood-2018-12-893917
State	Published - Apr 4 2019

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2018-12-893917

Cite this

@article{16d428a6fee3440fa4c3b5b2f6a18b5b,

title = "Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms",

author = "{on behalf of the Mayo Clinic Histiocytosis Working Group} and Gaurav Goyal and Denise Lau and Nagle, {Alison M.} and Robert Vassallo and Rech, {Karen L.} and Ryu, {Jay H.} and Davidge-Pitts, {Caroline J.} and {Oliver Tobin}, W. and Koster, {Matthew J.} and {Nora Bennani}, N. and Shah, {Mithun V.} and Liu, {Minetta C.} and Go, {Ronald S.}",

note = "Funding Information: This work was supported by the Mayo Clinic Cancer Center (grant P30 CA015083 from the National Institutes of Health, National Cancer Institute) and the Center for Individualized Medicine. Funding Information: Conflict-of-interest disclosure: A.M.N. and D.L. are employees of Tempus Labs. R.V. has received research funding from Pfizer, Bristol-Myers-Squibb, and Sun Pharma. W.O.T. has received research funding from Mallinckrodt. The remaining authors declare no competing financial interests.",

year = "2019",

month = apr,

day = "4",

doi = "10.1182/blood-2018-12-893917",

language = "English (US)",

volume = "133",

pages = "1607--1610",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "14",

}

TY - JOUR

T1 - Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms

AU - on behalf of the Mayo Clinic Histiocytosis Working Group

AU - Goyal, Gaurav

AU - Lau, Denise

AU - Nagle, Alison M.

AU - Vassallo, Robert

AU - Rech, Karen L.

AU - Ryu, Jay H.

AU - Davidge-Pitts, Caroline J.

AU - Oliver Tobin, W.

AU - Koster, Matthew J.

AU - Nora Bennani, N.

AU - Shah, Mithun V.

AU - Liu, Minetta C.

AU - Go, Ronald S.

N1 - Funding Information: This work was supported by the Mayo Clinic Cancer Center (grant P30 CA015083 from the National Institutes of Health, National Cancer Institute) and the Center for Individualized Medicine. Funding Information: Conflict-of-interest disclosure: A.M.N. and D.L. are employees of Tempus Labs. R.V. has received research funding from Pfizer, Bristol-Myers-Squibb, and Sun Pharma. W.O.T. has received research funding from Mallinckrodt. The remaining authors declare no competing financial interests.

PY - 2019/4/4

Y1 - 2019/4/4

UR - http://www.scopus.com/inward/record.url?scp=85064315918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064315918&partnerID=8YFLogxK

U2 - 10.1182/blood-2018-12-893917

DO - 10.1182/blood-2018-12-893917

M3 - Letter

C2 - 30696619

AN - SCOPUS:85064315918

SN - 0006-4971

VL - 133

SP - 1607

EP - 1610

JO - Blood

JF - Blood

IS - 14

ER -

Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this